Oxycodone News and Research

RSS

Scientists demonstrate new approach for quickly assembling drug-like compounds

A team of scientists anchored at Yale University has demonstrated a new, highly versatile approach for quickly assembling drug-like compounds, establishing a broad new route to drug discovery and medical treatment.

11 Feb 2013

Low testosterone levels occur more often among men on long-acting opioids

Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain.

2 Feb 2013

Study: OEND effectively addresses epidemic of fatal opioid overdose

In a study of communities in Massachusetts with high numbers of opioid overdose deaths, the implementation of overdose education and naloxone distribution (OEND) was associated with a significant reduction in opioid overdose death rates.

2 Feb 2013

QrxPharma to resubmit MOXDUO NDA with FDA

QRxPharma Limited announced today that the steps necessary for approval of immediate release MOXDUO have been clarified with the United States Food and Drug Administration (FDA).

17 Jan 2013

State roundup: Maine hospitals fighting for timely Medicaid payments

New York police plan to distribute "bait bottles" of fake pain-killers equipped with invisible GPS devices in a drive to combat the scourge of pharmacy robberies by addicts and sellers looking for oxycodone tablets, which can fetch more than $80 per pill on the street.

17 Jan 2013

First Edition: January 16, 2013

Today's headlines include reports examining how mental health issues play a role in efforts to curb gun violence and expand gun control efforts.

16 Jan 2013

Roundup: Medicaid waiver challenges in Texas; Detailing Sandy's impact on NYC's mental care

By 2012's end, health care providers across Texas will have submitted proposals to state leaders to transform the way they care for the poor and uninsured. They have been spurred by a Medicaid waiver Texas officials sought and received in 2011 from the federal government, one that ties financing to cooperation, cost efficiency and better patient outcomes.

2 Jan 2013

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Study examines public health impact of tamper resistant extended-release oxycodone

This is the first epidemiological study to examine the public health impact of a tamper resistant extended-release oxycodone (ORF). ER oxycodone was reformulated with physicochemical barriers to crushing and dissolving intended to reduce abuse through non-oral routes of administration.

16 Nov 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Prescription pain medication abuse on the rise among current generation of adolescents

A new study by the University of Colorado Denver reveals that today's adolescents are abusing prescription pain medications like vicodin, valium and oxycontin at a rate 40 percent higher than previous generations.

17 Oct 2012

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.

16 Oct 2012

Top-line results from Pfizer’s ALO-02 Phase 3 study on chronic non-cancer pain

Pfizer Inc. announced top-line results today from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.

12 Oct 2012

QRxPharma, Paladin execute licensing agreement for MOXDUO

QRxPharma Limited announced today execution of a licensing agreement with Paladin Labs Inc. for the Canadian commercialisation rights to MOXDUO, a patented, immediate release formulation of morphine and oxycodone.

10 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Study sheds new light on potential habit-forming properties of tramadol

A study by a team of University of Kentucky researchers has shed new light on the potential habit-forming properties of the popular pain medication tramadol, in research funded by the National Institute on Drug Abuse.

27 Sep 2012

Real-time prescription system reduces inappropriate prescribing of medications

A centralized prescription network providing real-time information to pharmacists in British Columbia, Canada, resulted in dramatic reductions in inappropriate prescriptions for opioid analgesics and benzodiazepines, widely used and potentially addictive drugs. The findings are reported in a study in CMAJ (Canadian Medical Association Journal).

5 Sep 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Electronic PMP use may have impact on demand for drug treatment programs, painkiller abuse

A Rhode Island Hospital researcher has found that the use of electronic prescription drug monitoring programs (PMPs) may have a significant impact on the demand for drug treatment programs and how prescribers detect and respond to abuse of painkillers.

17 Aug 2012